Effects of spironolactone in hypokalemic CAPD patients

Effects of spironolactone in hypokalemic CAPD patients: A Double-blinded placebo Controlled Trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20130314001

Enrollment

Registered

2013-03-14

Start date

2013-03-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end stage renal disease patients on CAPD CAPD Hypokalemia spironolactone serum potassium

Interventions

oral spironolactone in hypokalemic CAPD pateints with titrated oral potassium dose to maintain normal serum potassium,oral placebo with titrated oral potassium dose to maintain normal serum potassium

Active Comparator Drug,Placebo Comparator Drug

spironolactone,placebo

Eligibility

Sex/Gender

All

Age

20 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. ESRD patients on CAPD 2. history of hypokalemia

Exclusion criteria

Exclusion criteria: 1. history of hyperkalemia 2. participation in interventional study in the previous 3 months

Design outcomes

Primary

Measure	Time frame
serum potassium every two weeks serum potassium Milliequivalent per litre	—

Secondary

Measure	Time frame
potassium excretion rate at the end of treatment daily potassium excretion in urine and dialysate,dose of potassium replacement every two weeks dose of oral potassium replacement	—

Countries

Thailand

Contacts

Public Contactsomchai yongsiri

unaffiliated

syongsiri@yahoo.com66810011018

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026